PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
1.300
+0.235 (22.07%)
At close: Oct 27, 2026, 4:00 PM EDT
1.340
+0.040 (3.08%)
After-hours: Oct 27, 2026, 7:59 PM EDT
PDS Biotechnology Employees
PDS Biotechnology had 21 employees as of December 31, 2025. The number of employees decreased by 3 or 12.50% compared to the previous year. That makes PDS Biotechnology the 38,225th largest employer in the world and 5,490th in the United States.
Employees
21
Change (1Y)
-3
Growth (1Y)
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$1,603,427
Market Cap
94.22M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 21 | -3 | -12.50% |
| Dec 31, 2024 | 24 | -1 | -4.00% |
| Dec 31, 2023 | 25 | -1 | -3.85% |
| Dec 31, 2022 | 26 | 4 | 18.18% |
| Dec 31, 2021 | 22 | 7 | 46.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tonix Pharmaceuticals Holding | 142 |
| Inovio Pharmaceuticals | 112 |
| ImmuCell | 73 |
| Tenaya Therapeutics | 70 |
| PMV Pharmaceuticals | 54 |
| Milestone Pharmaceuticals | 38 |
| Genelux | 26 |
| NeurAxis | 24 |
PDSB News
- 7 days ago - PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors - GlobeNewsWire
- 12 days ago - PDS Biotechnology Transcript: KOL event - Transcripts
- 13 days ago - PDS Biotechnology registers to sell 16.5M shares of common stock for holders - TheFly
- 13 days ago - PDS Biotechnology Registration statement: Registration filing - Filings
- 21 days ago - PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases - GlobeNewsWire
- 5 weeks ago - PDS announces publication of results from Phase 2 trial of PDS0101 - TheFly
- 5 weeks ago - PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology - GlobeNewsWire
- 5 weeks ago - PDS Biotechnology Slides: Corporate presentation - Filings